Fulcrum Therapeutics (NASDAQ:FULC) Shares Up 7.8% – What’s Next?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) traded up 7.8% on Tuesday . The stock traded as high as $10.20 and last traded at $10.2490. 537,878 shares were traded during mid-day trading, a decline of 32% from the average session volume of 790,283 shares. The stock had previously closed at $9.51.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Cantor Fitzgerald boosted their target price on Fulcrum Therapeutics from $15.00 to $24.00 and gave the company an “overweight” rating in a research note on Monday, December 8th. Bank of America increased their price target on shares of Fulcrum Therapeutics from $6.00 to $7.00 and gave the stock an “underperform” rating in a research note on Tuesday, December 9th. JPMorgan Chase & Co. assumed coverage on Fulcrum Therapeutics in a research note on Monday. They issued an “overweight” rating and a $20.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Wednesday, October 8th. Finally, Royal Bank Of Canada raised their price objective on Fulcrum Therapeutics from $7.00 to $10.00 and gave the company a “sector perform” rating in a research report on Monday, December 8th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $19.11.

Fulcrum Therapeutics Price Performance

The business has a 50 day moving average price of $10.70 and a 200 day moving average price of $8.79. The stock has a market capitalization of $554.73 million, a PE ratio of -8.69 and a beta of 3.20.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings results on Wednesday, October 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.02). On average, equities analysts expect that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current year.

Insider Activity

In related news, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $13.98, for a total transaction of $58,368,443.22. Following the completion of the sale, the insider owned 6,053,960 shares of the company’s stock, valued at $84,634,360.80. This trade represents a 40.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert J. Gould sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $11.87, for a total transaction of $178,050.00. Following the completion of the transaction, the director owned 469,864 shares of the company’s stock, valued at approximately $5,577,285.68. The trade was a 3.09% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 4,205,139 shares of company stock valued at $58,711,943 over the last ninety days. Corporate insiders own 7.00% of the company’s stock.

Institutional Trading of Fulcrum Therapeutics

Several institutional investors have recently added to or reduced their stakes in FULC. Suvretta Capital Management LLC raised its stake in shares of Fulcrum Therapeutics by 5.9% in the third quarter. Suvretta Capital Management LLC now owns 5,381,000 shares of the company’s stock worth $49,505,000 after purchasing an additional 298,100 shares during the last quarter. Nantahala Capital Management LLC boosted its position in shares of Fulcrum Therapeutics by 8.9% during the third quarter. Nantahala Capital Management LLC now owns 4,670,784 shares of the company’s stock valued at $42,971,000 after buying an additional 382,485 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in Fulcrum Therapeutics by 53.0% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,589,000 shares of the company’s stock worth $31,572,000 after buying an additional 1,589,000 shares in the last quarter. Balyasny Asset Management L.P. raised its position in Fulcrum Therapeutics by 8.4% in the 3rd quarter. Balyasny Asset Management L.P. now owns 1,450,480 shares of the company’s stock worth $13,344,000 after buying an additional 112,266 shares during the last quarter. Finally, Boothbay Fund Management LLC raised its position in Fulcrum Therapeutics by 104.2% in the 3rd quarter. Boothbay Fund Management LLC now owns 678,414 shares of the company’s stock worth $6,241,000 after buying an additional 346,136 shares during the last quarter. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.